Moderna Inc.
Moderna Stockholders Approve Key Proposals at 2025 Annual Meeting
Summary
On April 30, 2025, Moderna, Inc. held its Annual Meeting of Stockholders where key proposals were approved. Stockholders elected three directors: Noubar Afeyan, Stéphane Bancel, and François Nader. An advisory vote approved the compensation of named executive officers, and the appointment of Ernst & Young LLP as the independent registered public accounting firm was ratified.
Profitelligence Alerts
Get alerts for MRNA
Be first to know when Moderna Inc. files with the SEC.
Filing Categories
Advertisement
About Moderna Inc.
Moderna Inc. is a biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Its primary function is to research and produce a broad spectrum of vaccines and therapeutics by leveraging its proprietary mRNA technology platform. Moderna is notably recognized for its pivotal role in the healthcare and pharmaceutical sector, particularly due to its development of one of the first COVID-19 vaccines to receive emergency use authorization. The company’s pipeline extends beyond infectious diseases, targeting therapeutic areas such as oncology, cardiovascular diseases, and rare genetic disorders. Headquartered in Cambridge, Massachusetts, Moderna takes a leading position in the biotechnology industry through its innovative approach to drug development, emphasizing rapid advancement from concept to clinical application. The company plays a crucial role in addressing global health challenges through its cutting-edge mRNA-based solutions.
Official SEC Documents
Advertisement